勃林格殷格翰生产的思力华怎么样？

In 2014, the drug developed by Boehringer Ingelheim was approved for marketing in my country, bringing a more efficient, safe and convenient new treatment option to COPD patients. Boehringer Ingelheim was founded by Albert Boehringer in 1885. Over the past century, it has adhered to the tradition of "innovation demonstrates value and R&D drives growth". The company extends from the Rhine River in Germany to more than 40 countries and regions around the world. Core businesses include prescription pharmaceuticals, animal health and biopharmaceuticals.

How about Spiriva produced by Boehringer Ingelheim?

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that causes shortness of breath and coughing. Respimat helps open the airways, making it easier for air to move in and out of the lungs. In vivo and in vitro studies have shown that Slihua has a dose-dependent and sustainable 24-hour inhibition of methacholine-induced bronchoconstriction. Sliva has outstanding localization selectivity in its dilation effect on bronchial tubes.

The approval of Siliva was based on data from two key phase III trials, TONADO-1 and -2. The study involved more than 5,000 COPD patients. Data showed that compared with placebo, tiotropium bromide, and olodaterol monotherapy, Slivar resulted in a statistically significant improvement in patients' lung function (FEV1) and had a similar safety profile to tiotropium bromide or olodaterol.

In addition to breathing problems, normal use of Spirava can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life. It has significant significance for the treatment of COPD patients.

The above is an introduction to the effects produced by Boehringer Ingelheim. I hope it will be helpful to you.

Recommended related hot articles: /newsDetail/88960.html